Swiss Software Stock News

SWX:EFGN
SWX:EFGNCapital Markets

EFG International (SWX:EFGN) Margin Decline To 19.6% Tests Profitability Narrative

EFG International (SWX:EFGN) has reported its FY 2025 results with second half revenue of CHF 864.5 million and basic EPS of CHF 0.34, alongside net income excluding extra items of CHF 112.8 million. The group has seen revenue move from CHF 753.4 million and basic EPS of CHF 0.49 in the second half of 2024 to CHF 793.8 million and basic EPS of CHF 0.71 in the first half of 2025. Trailing twelve month revenue of CHF 1.66 billion and basic EPS of CHF 1.03 set the broader context for today’s...
SWX:CPHN
SWX:CPHNForestry

CPH Group (SWX:CPHN) Margin Surge And 402% EPS Jump Challenge Cautious Narratives

CPH Group (SWX:CPHN) has reported fresh numbers for FY 2025, with second half revenue of CHF158.1 million and basic EPS of CHF1.04, alongside trailing 12 month revenue of CHF334.1 million and EPS of CHF3.90 that reflect a very large 402.6% earnings jump over the last year and a net margin that has increased to 7% from 1%. The company has reported revenue rising from CHF146.4 million and EPS of CHF2.23 in the second half of 2024 to CHF175.9 million and EPS of CHF2.85 in the first half of...
SWX:NESN
SWX:NESNFood

Nestlé Reshapes Portfolio Under New CEO To Refocus Growth Pillars

Nestlé (SWX:NESN) is overhauling its business under new CEO Philipp Navratil. The company is selling its remaining ice cream operations to Froneri. Nestlé is reorganizing around four divisions: coffee, petcare, nutrition, and food & snacks. A potential sale process has started for its waters and premium beverages segment. Executive changes include Anna Mohl stepping down after Health Science was folded into the new Nutrition division. Nestlé is one of the largest global consumer packaged...
SWX:SUNN
SWX:SUNNTelecom

Sunrise Communications Q4 Losses Narrow Yet Still Test Bullish Turnaround Narrative

Sunrise Communications (SWX:SUNN) has wrapped up FY 2025 with Q4 revenue of CHF 788.8 million and a net income loss of CHF 50.1 million, while the trailing twelve months show revenue of CHF 2.98 billion alongside a loss of CHF 112.2 million. The company has seen quarterly revenue move in a tight band between CHF 722.1 million and CHF 788.8 million from Q1 to Q4 2025, with basic EPS ranging from a loss of CHF 0.022 in Q1 to a loss of CHF 0.075 in Q3. This keeps the spotlight squarely on when...
SWX:NOVN
SWX:NOVNPharmaceuticals

Is It Too Late To Consider Novartis (SWX:NOVN) After A 1-Year 35% Rally?

If you are wondering whether Novartis shares still offer value at current levels, this article walks through what the numbers say about the price you are paying versus what you are getting. The stock last closed at $126.48, with returns of 2.2% over 7 days, 10.7% over 30 days, 16.6% year to date, 35.5% over 1 year, 85.7% over 3 years and 104.7% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent headlines around Novartis have...
SWX:AMS
SWX:AMSSemiconductor

Assessing ams-OSRAM (SWX:AMS) Valuation After Open System Protocol Advances Toward ISO Standard Status

ams-OSRAM (SWX:AMS) has attracted fresh attention after its Open System Protocol for automotive lighting progressed toward ISO standard status, positioning the company more firmly within next generation vehicle electronics architectures. See our latest analysis for ams-OSRAM. That progress toward an ISO standard comes shortly after ams-OSRAM reported 2025 results that showed sales of €3,323m with a net loss of €130m, alongside guidance for first quarter 2026 revenues between €710m and €810m...
SWX:ROG
SWX:ROGPharmaceuticals

Roche Trials Signal New Gazyva Opportunity And Fresh Research Leadership

Roche Holding (SWX:ROG) reported phase III trial results showing Gazyva achieved statistically significant and clinically meaningful outcomes in primary membranous nephropathy. The company highlighted that Gazyva could become the first therapy specifically indicated for this rare kidney disease, subject to regulatory review and approval. Roche also appointed Mark Dawson as Head of Pharma Research and Early Development, adding a globally recognized cancer researcher to its senior...
SWX:BSLN
SWX:BSLNBiotechs

High Growth Tech Stocks with Promising Global Potential

Amidst a backdrop of declining U.S. stock indexes and heightened concerns over AI's disruptive potential, the global market landscape remains dynamic, with significant employment gains in the U.S. affecting rate cut expectations and European markets experiencing volatility due to similar AI apprehensions. In this environment, identifying high growth tech stocks with promising global potential requires an understanding of how these companies can navigate current challenges such as...
SWX:COPN
SWX:COPNPharmaceuticals

Assessing Cosmo Pharmaceuticals (SWX:COPN) Valuation After Strong Revenue Update And Share Price Momentum

Cosmo Pharmaceuticals (SWX:COPN) has drawn attention after a strong share price move in recent months, prompting investors to look more closely at how its gastroenterology, dermatology, and healthtech portfolio lines up with current expectations. See our latest analysis for Cosmo Pharmaceuticals. At a share price of CHF122.6, Cosmo Pharmaceuticals has logged a 9.66% 1 month share price return and an 81.90% 3 month share price return. The 1 year total shareholder return of 89.84% suggests...
SWX:BEKN
SWX:BEKNBanks

European Dividend Stocks With Up To 4.8% Yield

As European markets experience volatility amid global concerns over AI disruptions, the pan-European STOXX Europe 600 Index has managed to hit new highs, reflecting resilience in the face of these challenges. In this environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate uncertain times.
SWX:AMRZ
SWX:AMRZBasic Materials

Amrize (SWX:AMRZ) Margin Plateau At 10% Tests Bullish Earnings Expansion Narrative

Amrize (SWX:AMRZ) just closed FY 2025 with Q4 revenue of US$2.8b, Basic EPS of US$0.54 and net income of US$298m, while trailing twelve month revenue came in at US$11.8b with Basic EPS of US$2.14 and net income of US$1.2b. The company has seen quarterly revenue move from US$2.1b in Q1 2025 to a peak of US$3.7b in Q3 before Q4’s US$2.8b, with EPS ranging from a Q1 loss of US$0.15 per share to US$0.99 in Q3 and US$0.54 in Q4. This gives investors a full year view of how the earnings power has...
SWX:BAER
SWX:BAERCapital Markets

Julius Bär Gruppe (SWX:BAER) Valuation Check As India Expansion Plans Move Forward

Julius Bär Gruppe (SWX:BAER) is expanding its footprint in India, joining other global financial firms in setting up global capability centres and hiring across cities such as Chennai and Hyderabad. See our latest analysis for Julius Bär Gruppe. At a share price of CHF66.0, Julius Bär Gruppe’s recent India expansion news arrives after a 13.71% 90 day share price return and an 18.79% 1 year total shareholder return. This may indicate that momentum has been building rather than fading. If this...
SWX:BSLN
SWX:BSLNBiotechs

Basilea Pharmaceutica (SWX:BSLN) Margin Slide Challenges Bullish Growth Narratives After FY 2025 First Half

Basilea Pharmaceutica (SWX:BSLN) has just posted its FY 2025 numbers with first half revenue of CHF103.96 million and basic EPS of CHF1.29, following FY 2024 second half revenue of CHF132.25 million and basic EPS of CHF4.70. The company has seen revenue move from CHF76.29 million in FY 2024 first half to CHF132.25 million in second half and then CHF103.96 million in FY 2025 first half, while basic EPS shifted from CHF1.72 to CHF4.70 and then CHF1.29. This sets up a results picture that puts...
SWX:SPSN
SWX:SPSNReal Estate

Swiss Prime Site’s Valuation After Dividend Hike And Stronger 2025 Earnings

Swiss Prime Site (SWX:SPSN) drew fresh attention after reporting full year 2025 earnings along with a proposed dividend increase to CHF 3.50 per share, with shareholders set to vote at the 12 March 2026 AGM. See our latest analysis for Swiss Prime Site. The proposed dividend increase and solid full year 2025 earnings come after a strong run in the share price, with a 90 day share price return of 17.63%, a 1 year total shareholder return of 29.71% and a 3 year total shareholder return of...
SWX:ALSN
SWX:ALSNElectronic

A Look At ALSO Holding (SWX:ALSN) Valuation After Earnings Call And Higher Dividend Announcement

Earnings call and dividend decision draw focus to ALSO Holding (SWX:ALSN) ALSO Holding (SWX:ALSN) is back on investor radars after its 2025 earnings call on 17 February 2026 coincided with the announcement of an annual dividend of CHF 5.30 per share. See our latest analysis for ALSO Holding. The earnings call and dividend announcement came against a weak backdrop, with a 1 day share price return of 31.17% decline and a 1 year total shareholder return of 46.43% decline suggesting momentum has...
SWX:ALC
SWX:ALCMedical Equipment

Is There Now An Opportunity In Alcon (SWX:ALC) After A 23.6% Share Price Drop

This article is designed to help you think clearly about whether Alcon's current share price fairly reflects its potential or if the market might be mispricing it. Alcon closed at $61.90, with a 1.4% gain over the last 7 days, a 3.2% decline over 30 days, a 2.6% decline year to date, and a 23.6% decline over the past year, which may catch the eye of investors reassessing the balance between opportunity and risk. Recent headlines around Alcon have focused on its position within healthcare and...
SWX:SGKN
SWX:SGKNBanks

A Look At St. Galler Kantonalbank (SWX:SGKN) Valuation After Full-Year Results And Dividend Announcement

Why St. Galler Kantonalbank’s latest results matter for shareholders St. Galler Kantonalbank (SWX:SGKN) has caught investor attention after reporting full year 2025 results, with higher net interest income and net income, alongside an annual dividend announcement of CHF 20.00 per share. See our latest analysis for St. Galler Kantonalbank. The latest earnings and dividend news comes after a strong run in the share price, with a 90 day share price return of 18.10% and a 1 year total shareholder...
SWX:BCVN
SWX:BCVNBanks

European Dividend Stocks To Consider In February 2026

As European markets navigate volatility amid AI disruption concerns and digest strong U.S. job data, the pan-European STOXX Europe 600 Index managed to hit a new high, reflecting resilience in the region's economy. In such an environment, dividend stocks can offer investors a measure of stability and income potential, making them an attractive consideration for those looking to balance growth with steady returns.
SWX:ABBN
SWX:ABBNElectrical

Is It Too Late To Consider ABB (SWX:ABBN) After Its Strong Multi‑Year Share Price Run?

If you are wondering whether ABB is still fairly priced after a strong run, this article will walk through what the current share price might be implying about value. ABB's share price closed at CHF 69.80, with returns of 1.7% over 7 days, 13.3% over 30 days, 14.0% year to date, 34.5% over 1 year, 139.7% over 3 years and 215.6% over 5 years. This raises the question of what is already reflected in the price. Recent news around ABB has focused on its position as a global industrial technology...
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis (SWX:NOVN): Are Renal Bets And Radiopharmaceuticals Quietly Reshaping Its Long-Term Growth Mix?

In early February 2026, Novartis reported final Phase III ALIGN data showing Vanrafia® (atrasentan) slowed kidney function decline in adults with IgA nephropathy, alongside a new long-term Actinium-225 supply agreement from Niowave to support its radioligand therapy portfolio for difficult-to-treat cancers. Together, these updates highlight Novartis’ effort to build depth in both renal disease and radiopharmaceutical oncology, reinforcing the importance of specialized therapies and secure...
SWX:SREN
SWX:SRENInsurance

3 European Dividend Stocks Yielding Up To 5.3%

As European markets navigate volatility, with the STOXX Europe 600 Index recently hitting a new high before settling nearly unchanged, investors are keenly observing economic indicators such as employment growth and GDP expansion in the eurozone. Amidst these dynamics, dividend stocks have gained attention for their potential to provide steady income; qualities like strong cash flow and a history of consistent payouts can make them appealing choices in uncertain market conditions.
SWX:SCMN
SWX:SCMNTelecom

Swisscom (SWX:SCMN) Valuation Check After Earnings Update And CHF 26 Dividend Proposal

Why Swisscom’s latest earnings and dividend move matter for shareholders Swisscom (SWX:SCMN) shares are in focus after the company paired its full year 2025 earnings release with a proposed CHF 26.00 per share annual dividend, drawing attention to both profitability and cash returns. See our latest analysis for Swisscom. That mix of a lower net income figure alongside solid operational progress and a proposed CHF 26.00 dividend appears to have caught the market’s eye. A 1 month share price...
SWX:LISN
SWX:LISNFood

Is Lindt’s DubaiStyle Expansion a Clue to Its Everyday Indulgence Strategy for (SWX:LISN) Investors?

In February 2026, Lindt & Sprüngli confirmed the return of its sold‑out DubaiStyle Chocolate to Canadian shelves, reintroducing the 150g bar and adding a new 40g snackable format crafted with smooth milk chocolate, pistachio filling and kadayif pastry. The launch of a portable 40g DubaiStyle bar alongside the original 150g format highlights how Lindt is using premium, culturally inspired recipes to broaden everyday indulgence occasions. We’ll now examine how expanding DubaiStyle into a new...